NEW PRODUCT COMING SOON! JANUARY 2025
Catalog No.: 107650
Net Contents: ADP Reagent 1 x 0.5 mL
Arachidonic Acid Reagent 1 x 0.5 mL
Collagen Reagent 1 x 0.5 mL
Epinephrine Reagent 1 x 0.5 mL
Ristocetin Reagent 1 x 0.5 mL
AGG/PAK™ 5 COMBO KIT
Platelet Aggregation Reagent Combination Kit
AGG/PAK™ 5 Combo Kit: Unlocking Enhanced Efficiency for Platelet Aggregation Testing
AGG/PAK™ 5 Combo Kit is a convenience kit containing a combination of routine platelet aggregation reagents used to elicit aggregation and / or agglutination responses in Platelet Rich Plasma (PRP). This Kit includes ADP, Arachidonic Acid, Collagen, Epinephrine, and Ristocetin Reagents.
-
Evaluates Platelet Function Disorders
-
Identifies von Willebrand Disease (vWD) Using Ristocetin Induced Platelet Aggregation Testing (RIPA)
-
Follows ISTH / SCC Proposed Aggregation Panel
-
Assesses Anti-Platelet Therapy Effectiveness
-
Offers Insights into Clot Formation Dynamics
-
Aids in Thrombotic Event Prevention
-
Simplifies Laboratory Inventory Control
NEW PRODUCT COMING SOON! JANUARY 2025
PRODUCT DETAILS
The AGG/PAK™ 5 Combo Kit effectively identifies abnormalities in patients with various acquired and inherited platelet disorders. Laboratories can evaluate patient responses to anti-platelet therapies, ensuring optimal treatment plans. By analyzing platelet aggregation, the Combo Kit provides valuable information on the dynamics of clot formation, aiding in the early detection and prevention of thrombotic events. Additionally, the Combo Kit includes Ristocetin Reagent, necessary for Ristocetin-Induced Platelet Aggregation (RIPA), essential for identifying von Willebrand Disease (vWD). The AGG/PAK™ 5 Combo Kit meets CLIA, ISTH, and other regulatory requirements, ensuring the highest standards of quality and compliance.
ADP Reagent is a lyophilized preparation of Adenosine-5’-Diphosphate, a crucial component in platelet aggregation. ADP acts as an agonist by binding to platelet receptors such as P2Y1 and P2Y12, initiating intracellular signaling cascades that lead to platelet activation and aggregation. This process is essential for understanding clot formation dynamics and evaluating anti-platelet therapy efficacy, as ADP induces the release of secondary mediators like Thromboxane A2 (TX A2).
Arachidonic Acid Reagent, a lyophilized preparation of the Sodium Salt of Arachidonic Acid, is an essential fatty acid involved in platelet activation and aggregation. Upon binding to platelet receptors, it is enzymatically converted to Thromboxane A2 (TX A2), which facilitates signaling cascades leading to platelet shape changes and aggregation. This reagent is vital for assessing platelet function and the effectiveness of anti-platelet therapies.
Collagen Reagent, a lyophilized preparation of Soluble Calf Skin (Type 1), induces platelet activation by binding to glycoprotein receptors such as GP VI on the platelet surface. This interaction triggers intracellular signaling, causing rapid platelet shape change and the release of thrombotic compounds that recruit additional platelets. Collagen Reagent is essential for evaluating platelet function related to collagen-induced activation abnormalities and assessing anti-platelet therapies.
Epinephrine Reagent, a stabilized and lyophilized preparation of L-Adrenaline, activates α2-adrenergic receptors on the platelet surface, initiating intracellular signaling cascades that lead to platelet activation without shape change. While it can enhance responses to other agonists, Epinephrine is a weak agonist and may not elicit a response in all individuals. This reagent helps clinicians assess platelet function and the effectiveness of anti-platelet therapies.
Ristocetin Reagent, a lyophilized preparation of Ristocetin A Sulfate, is used in Ristocetin Induced Platelet Aggregation (RIPA) testing. It interacts with von Willebrand Factor (vWF), causing a conformational change that exposes binding sites for platelet glycoprotein Ib (GP Ib). This interaction initiates platelet adhesion and aggregation, crucial for diagnosing von Willebrand Disease (vWD) and other platelet function disorders. RIPA testing provides valuable insights into platelet function and vWF activity.
Please explore the literature provided on this page, encompassing the AGG/PAK™ 5 Combo Kit Product Data Sheet, Routine Agonist Expected Results Chart, and the AGG/PAK™ 5 Combo Kit Instruction for Use (IFU), along with the AGG/PAK™ 5 Combo Kit Safety Data Sheet (SDS) — both available in six languages. Additionally, for our European and United Kingdom customers and distributors, review the AGG/PAK™ 5 Combo Kit EU Declaration of Conformity and the AGG/PAK™ 5 Combo Kit UK Declaration of Conformity, to ensure compliance and understanding tailored specifically for these regions. This information is crucial for a comprehensive grasp of the product details and specifications.
YOU MAY ALSO BE INTERESTED IN:
